Folotyn for Non-Hodgkin's Lymphoma Malone NY

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Local Companies

Myrna Sanchez
(518) 483-0482
183 Park St Ste 5
Malone, NY
Sun Hua Liauw, MD
315-268-9314
23 4th St
Malone, NY
Eastchester Center For Cancer Care
(718) 732-4000
2330 Eastchester Rd
Bronx, NY
Advanced Rockland Radiation Oncology Service of Rockland
(845) 727-0828
111 N Highland Ave
Nyack, NY
Eanelli Thomas R MD
(845) 727-0828
111 N Highland Ave
Nyack, NY
Betty Danes
518-425-3379
PO Box 140
Chateaugay, NY
Betty Shannon Danes, MD
518-425-3379
PO Box 140
Chateaugay, NY
Sponzo Robert W MD
(518) 926-6620
102 Park St
Glens Falls, NY
Sound Shore Medical Center of Westchester
(914) 632-5000

New Rochelle, NY
Samaritan Hospital
(518) 271-3220
2215 Burdett Ave
Troy, NY
Data Provided by:
  

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Donor Stem-Cell Transplant for Acute Myeloid Leukemia Malone NY
For most patients with acute myeloid leukemia (AML) who come out of remission, donor stem cells appear to offer the best shot at survival, a new analysis shows.
- Green Tea and Hematologic Malignancies Malone NY